ABSTRACT
BACKGROUND: Chronic plaque psoriasis is frequently associated with metabolic disorders including obesity. Antitumour necrosis factor α treatments can induce body-weight increase in patients with psoriasis. Information on the effect of ustekinumab on body weight is not available. OBJECTIVES: To investigate whether therapy with ustekinumab is associated with changes in body mass index (BMI) in patients with chronic plaque psoriasis. METHODS: A prospective, multicentre study comparing the changes in BMI in two closed cohorts of patients with psoriasis during 7-month treatment with ustekinumab (n = 79) or infliximab (n = 83). RESULTS: Patients treated for 7 months with infliximab showed a significant (P < 0.001) increase in mean BMI (2.1 ± 4.5%) and body weight (2.5 ± 3.3 kg) compared with patients treated with ustekinumab (0.1 ± 3.3%; 0.6 ± 1.1 kg). Some 45% of patients treated with infliximab had a BMI increase > 2%, compared with only 11% of those receiving ustekinumab (P = 0.01). In the multivariate analysis, all other clinical parameters predicted the BMI increase, except for the use of infliximab. At month 7, 96% of patients treated with infliximab and 82% of patients treated with ustekinumab achieved at least a 50% improvement from their baseline psoriasis area and severity index (PASI 50), and 69% of the infliximab group compared with 58% of the ustekinumab group achieved at least PASI 75. There was no difference in the proportion of PASI 50 and PASI 75 responders between the two groups. CONCLUSIONS: In contrast to infliximab, ustekinumab does not increase BMI in patients with chronic plaque psoriasis. This difference could be taken into account in the selection of biologics when treating patients with psoriasis.
Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Body Mass Index , Dermatologic Agents/adverse effects , Psoriasis/drug therapy , Weight Gain/drug effects , Adult , Antibodies, Monoclonal/adverse effects , Biological Products/adverse effects , Body Weight/drug effects , Cohort Studies , Female , Humans , Infliximab , Male , Middle Aged , Prospective Studies , Treatment Outcome , UstekinumabABSTRACT
Adolescence constitutes a period of nutritional vulnerability due to increased dietary requirements for growth and development and special dietary habits. A pilot trial was performed to evaluate the dietary calcium utilization among a sample of Spanish boys on their usual diets, in which the calcium intake and consumption of dairy products were as well examined. Nutrient and food intake was recorded using a 24-h dietary recall and a 2-d food consumption record for 21 subjects aged 11-14 years. Dietary calcium utilization was assessed by means of calcium intake in food and calcium output in faeces and urine as measured by flame atomic absorption spectrophotometry. Overall intake of dairy products was 399.3 +/- 22.1 g/d, and the single most consumed item was milk (72% of the total). An inverse relationship was found between dairy product consumption at breakfast (55% of the total) and BMI (p = 0.016, r = -0.5168). Dairy products contributed the majority of dietary calcium (66.9%). Mean calcium intake was 881.7 +/- 39.9 mg/d, 88% of the recommended value for Spanish adolescents. Net calcium absorption (271.7 +/- 51.7 mg/d) and retention (170.6 +/- 50.9 mg/d) seemed not to be sufficient to meet growth demands during puberty. The results shown that adolescents of the study absorbed 31% of dietary calcium and retained nearly 20% of the total intake, but dietary calcium intake and consumption of dairy products failed to meet recommended values. Optimizing calcium intake is of crucial importance among adolescents, to maximize calcium retention and to help prevent osteoporosis in later life.
Subject(s)
Calcium, Dietary/pharmacokinetics , Diet , Adolescent , Alkaline Phosphatase/blood , Calcium/blood , Calcium/urine , Calcium, Dietary/administration & dosage , Child , Dairy Products , Energy Intake , Feces/chemistry , Humans , Intestinal Absorption , Male , Parathyroid Hormone/blood , Pilot Projects , SpainABSTRACT
No disponible
Adolescence constitutes a period of nutritional vulnerability due to increaseddietary requirements for growth and development and special dietary habits. A pilottrial was performed to evaluate the dietary calcium utilization among a sample ofSpanish boys on their usual diets, in which the calcium intake and consumption ofdairy products were as well examined. Nutrient and food intake was recorded usinga 24-h dietary recall and a 2-d food consumption record for 21 subjects aged 11-14years. Dietary calcium utilization was assessed by means of calcium intake in foodand calcium output in faeces and urine as measured by flame atomic absorption spectrophotometry.Overall intake of dairy products was 399.3±22.1 g/d, and the singlemost consumed item was milk (72% of the total). An inverse relationship was foundbetween dairy product consumption at breakfast (55% of the total) and BMI(p=0.016, r=-0.5168). Dairy products contributed the majority of dietary calcium(66.9%). Mean calcium intake was 881.7±39.9 mg/d, 88% of the recommended valuefor Spanish adolescents. Net calcium absorption (271.7±51.7 mg/d) and retention(170.6±50.9 mg/d) seemed not to be sufficient to meet growth demands duringpuberty. The results shown that adolescents of the study absorbed 31% of dietarycalcium and retained nearly 20% of the total intake, but dietary calcium intake andconsumption of dairy products failed to meet recommended values. Optimizing calciumintake is of crucial importance among adolescents, to maximize calcium retentionand to help prevent osteoporosis in later life
Subject(s)
Male , Child , Adolescent , Humans , Calcium, Dietary/pharmacokinetics , Diet , Alkaline Phosphatase/blood , Calcium/blood , Calcium/urine , Calcium, Dietary/administration & dosage , Dairy Products , Energy Intake , Feces/chemistry , Intestinal Absorption , Parathyroid Hormone/blood , Pilot Projects , SpainABSTRACT
No disponible
